Neonc Technologies Holdings (NTHI) FCF Margin (2024 - 2025)
Neonc Technologies Holdings (NTHI) posted quarterly FCF Margin of 14128.67% for Q1 2025, down 1446762.0% year-over-year from N/an in Q1 2024, and down 196.07% quarter-over-quarter from 4772.02% in Q4 2024.
Neonc Technologies Holdings (NTHI) FCF Margin (2024 - 2025) Analysis & Trends
Neonc Technologies Holdings (NTHI) has reported FCF Margin for 2 consecutive years, with 14128.67% the latest figure, recorded in Q1 2025.
- In Q1 2025, FCF Margin fell 1446762.0% year-over-year to 14128.67%; the TTM figure through Dec 2025 stood at 50922.6% (down 4584559.0% YoY), while the FY2025 annual figure was 52172.91%, down 4709591.0% from the prior year.
- FCF Margin retreated to 14128.67% in Q1 2025 per NTHI's latest filing, from 4772.02% in the prior quarter.
- Across five years, FCF Margin topped out at 338.95% in Q1 2024 and bottomed at 14128.67% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 70.82% |
| 10 | Neonc Technologies Holdings | 116.41 Mn | 116.41 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -14,128.67% |
| Dec 31, 2024 | -4,772.02% |
| Jun 30, 2024 | -1,591.02% |
| Mar 31, 2024 | 338.95% |